Loading the security overview…
Where the tokens are
Standardised from the company’s filings, newest period first, labelled with the company’s own fiscal calendar. A line the company does not report is left off rather than shown as zero; margins and free cash flow are worked out here, and only where every input is present.
| Line item | Q3 FY262026-06-30 | Q2 FY262026-03-31 | Q1 FY262025-12-31 | Q4 FY252025-09-30 | Q3 FY252025-06-30 | Q2 FY252025-03-31 | Q1 FY252024-12-31 | Q4 FY242024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $75.25M | $73.74M | $264.03M | $256.47M | $27.77M | $542.71M | $2.50M | $0 |
| Gross profit | $75.25M | $73.74M | $264.03M | $256.47M | $27.77M | $542.71M | $2.50M | $0 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — |
| Research and development | $198.22M | $173.25M | $177.20M | $174.69M | $162.37M | $133.10M | $137.00M | $135.83M |
| Selling, general and administrative | $47.12M | $41.74M | $46.02M | $37.68M | $30.95M | $28.41M | $26.91M | $26.38M |
| Operating expenses | $245.35M | $215.00M | $223.22M | $212.37M | $193.32M | $161.51M | $163.91M | $162.20M |
| Operating income | −$170.09M | −$141.26M | $40.81M | $44.11M | −$165.55M | $381.20M | −$161.41M | −$162.20M |
| Operating margin | -226.0% | -191.6% | 15.5% | 17.2% | -596.2% | 70.2% | -6456.5% | — |
| EBITDA | −$163.43M | −$134.89M | $47.20M | $50.49M | −$159.33M | $387.29M | −$156.18M | −$157.18M |
| Interest income | $16.94M | $16.87M | $9.69M | $9.05M | $11.02M | $9.62M | $7.60M | $7.17M |
| Interest expense | −$24.56M | −$23.85M | −$22.51M | −$21.69M | −$24.38M | −$21.64M | −$21.65M | −$14.65M |
| Income before taxes | −$178.91M | −$137.57M | $28.27M | $36.12M | −$179.09M | $369.62M | −$175.12M | −$172.80M |
| Income taxes | $11.00K | $7.00K | $29.00K | $20.00M | −$437.00K | $1.75M | $103.00K | $546.00K |
| Net income | −$178.92M | −$137.57M | $28.24M | $16.12M | −$178.65M | $367.86M | −$175.22M | −$173.34M |
| Net margin | -237.8% | -186.6% | 10.7% | 6.3% | -643.4% | 67.8% | -7008.7% | — |
| EPS, basic | −$1.36 | −$0.93 | $0.22 | −$0.18 | −$1.26 | $2.78 | −$1.39 | −$1.37 |
| EPS, diluted | −$1.36 | −$0.93 | $0.22 | −$0.18 | −$1.26 | $2.75 | −$1.39 | −$1.37 |
| Diluted shares | 143.38M | 142.42M | 140.71M | 133.76M | 139.04M | 134.48M | 124.85M | 119.78M |
Figures describe Arrowhead Pharmaceuticals shares, not any token. As of Aug 4, 2026, from Massive's standardised financials. The company reports these figures; a token's issuer holds the shares and reports nothing of its own here.